A Study of the HSP90 Inhibitor, STA-9090 in Subjects With Stage IIIB or IV Non-Small Cell Lung Cancer (NSCLC)

Inclusion Criteria:

Pathologically confirmed diagnosis of Stage IIIB (with pleural effusion) or Stage IV NSCLC with measurable disease by RECIST and evidence of progression
Availability of tissue for analysis
ECOG Performance Status 0 or 1
Adequate organ function as defined in the protocol.
Must be at least 18 years old and able and willing to sign a written informed consent document

Exclusion Criteria:

Poor venous access requiring an indwelling catheter for study drug administration
Women who are pregnant or lactating
Ventricular ejection fraction < or = to 55% at baseline
Any uncontrolled intercurrent illness